Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Phosphorylation of Tau Protein Inhibits Amyloid-beta Toxicity in Alzheimer’s Model

By Gerald M. Slutzky, PhD
Posted on 29 Nov 2016
A team of Australian Alzheimer's disease (AD) researchers have presented evidence suggesting that phosphorylation of tau protein in the early stages of the disease acts to protect against the toxicity of amyloid-beta (Abeta) plaques, and that this protective effect disappears as the disease progresses.

The prevailing idea among AD researchers has been that Abeta induced phosphorylation of tau, which in turn triggered the neuronal dysfunction that characterized the disease.

Investigators at the University of New South Wales (Sydney, Australia) worked with Alzheimer's disease mouse models and samples of brain tissue obtained from AD patients. More...
They reported in the November 18, 2016, issue of the journal Science that at least in early stages of the disease, site-specific phosphorylation of tau inhibited Abeta toxicity. This specific tau phosphorylation was mediated by the neuronal enzyme p38gamma (p38 mitogen-activated protein kinase) and interfered with postsynaptic toxic signaling complexes engaged by Abeta.

Depletion of p38gamma increased the severity of neuronal circuit aberrations, cognitive deficits, and premature lethality in a mouse model of AD, whereas increasing the activity of p38gamma abolished these deficits. Furthermore, mimicking site-specific tau phosphorylation alleviated Abeta-induced neuronal death and offered protection from its toxicity.

"This study has completely changed our understanding of what happens in the brain during the development of Alzheimer's disease," said senior author Dr. Lars Ittner, professor of medicine at the University of New South Wales. "Amyloid-beta induces toxicity in the neurons but the first step in tau phosphorylation is actually to decrease this toxicity. This is a completely new mindset; that the reason tau becomes modified is actually to protect from damage. We found that p38gamma, which initially offers protection, fades away early in the brains of people with AD, suggesting a loss of protection."

"We set out to find mediators of this progression, which led us quickly to our surprising finding. It was the opposite of what we expected. It was only when we changed our view of the process involved in the development of AD that these results started to make sense," said Dr. Ittner. "We used mice to screen for a very specific toxicity that we knew from previous work is involved in the progression of the disease. Part of our study involved reintroducing p38gamma and increasing its activity. We saw that, in mice, it could prevent memory deficits from happening, so it has true therapeutic potential. If we can stimulate that activity, we may be able to delay or even halt the progression of Alzheimer's disease."

Related Links:
University of New South Wales


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.